

Figure 3.13	Profiles of each concentration point (0.5, 1, and 1.5 µg/ml, respectively) of amlodipine, glimepiride and atorvastatin. Peaks are directly correlated to concentration.	51
Figure 3.14	Chromatogram of amlodipine, glimepiride, and atorvastatin using 240 nm wavelength	54
Figure 3.15	Chromatogram of amlodipine, glimepiride, and atorvastatin using 234 nm wavelength	54
Figure 3.16	Chromatogram of amlodipine, glimepiride, and atorvastatin in plasma using 234 nm wavelength	55
Figure 3.17	Chromatogram of amlodipine, glimepiride, and atorvastatin in plasma using 240 nm wavelength	56
Figure 3.18	Chromatogram of amlodipine, glimepiride, and atorvastatin at pH 7.8 of the mobile phase	57
Figure 3.19	Chromatogram of amlodipine, glimepiride, and atorvastatin at pH 8.0 of the mobile phase	57
Figure 3.20	Chromatogram of amlodipine, glimepiride, and atorvastatin at pH 8.2 of the mobile phase	57
Figure 3.21	Chromatogram of amlodipine, glimepiride, and atorvastatin following the addition of acid	59
Figure 3.22	Chromatogram of amlodipine, glimepiride, and atorvastatin following the addition of base	59
Figure 3.23	Chromatogram of amlodipine, glimepiride, and atorvastatin when setting the temperature at 28°C	61